Lexicon Pharma (LXRX) Tops Q4 EPS by 24c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.23 -0.45%
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.04), $0.24 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $110 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- GameStop (GME) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
